APRETUDE Clinical Trial header image

What the studies show

APRETUDE Clinical Trial header image

What the
studies show

Long-acting APRETUDE was proven superior at reducing the risk of getting HIV vs once-daily Truvada

Randomized, double-blind, active-controlled clinical trials were used to make the results of the study less likely to be biased.

In these clinical trials, participants were randomly assigned to receive either APRETUDE + Truvada placebo or Truvada + APRETUDE placebo. Participants and investigators did not know which medicine they were receiving.

Approximately 8,000 participants

Included at-risk HIV-1—negative cisgender men, transgender women, and cisgender women

APRETUDE patient 3
Three APRETUDE patients

Among the most diverse PrEP studies ever conducted.

Among the most diverse PrEP studies ever conducted.

Study 1: 4,566 HIV-1—negative cisgender men and transgender women at risk for getting HIV

On APRETUDE: 12 out of 2,278 people became HIV positive

On Truvada: 39 out of 2,281 people became HIV positive

More people stayed HIV negative on APRETUDE vs Truvada during the study
 

Participants were on the product for a median of 1.3 years. 

Results may vary.

HIV Infection Line Graph


Participants were on the product for a median of 1.3 years. 

Results may vary.

In Study 1

50% of US participants identified as Black/African-American men

12% of global participants identified as transgender women

18% of US participants identified as Hispanic/Latino

Nearly two-thirds of participants were under 30. The median age was 26

Study 2: 3,224 HIV-1—negative cisgender women at risk for getting HIV

On APRETUDE: 3 of 1613 people became HIV positive

On Truvada: 36 out of 1610 people became HIV positive

Significantly more women stayed HIV negative on APRETUDE vs Truvada during the study

Participants were on the product for a median of 1.2 years. 

Results may vary. 

Participants were on the product for a median of 1.2 years. 

Results may vary. 

In Study 2

3,224 women in Sub-Saharan Africa participated

Nearly half were younger than 25

APRETUDE is given every other month by a healthcare provider after initiation injections have been given 1 month apart for 2 consecutive months. Stay under a provider’s care while receiving APRETUDE. You must receive it as scheduled. If you will miss a scheduled injection by more than 7 days, call your provider right away.

Ready for long-acting PrEP?

Stay connected to APRETUDE

CBTWCNT220047